Dendreon Announces Interim Data from Phase 3 PROVENGE IMPACT Trial
SEATTLE, October 6, 2008 - Dendreon Corporation (Nasdaq: DNDN) announced today that it has completed the planned interim analysis READ MORE http://investor.dendreon.com/releasedetail.cfm...
PROMISING NEW CANCER THERAPIES ON THE HORIZON
Dendreon is focused on discovering, developing and commercializing novel therapeutics to fight cancer. Our pipeline includes active cellular immunother READ MORE http://www.dendreon.com/pipeline/
Dendreon is focused on discovering, developing and commercializing novel therapeutics to fight cancer. Our pipeline includes active cellular immunotherapy, monoclonal antibody and small molecule product candidates to treat a wide range of cancers.